Takeda Pharmaceutical Company Limited
HealthcareNYSE:TAK · New York Stock Exchange
+$0.04 today
Vol 3.76M · Avg 3.09M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Earnings Waterfall
Revenue to Net Income
Key Ratios
Analysis
$4.5T of revenue converted into $193.2B of net income for the selected period. Gross margin is 58.6% and net margin is 4.2%, showing how much revenue survives after costs and taxes. EPS is $60.38, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $4.8T +4.3% | $4.6T +7.5% | $4.3T +5.9% | $4.0T +12.8% | $3.6T | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $2.3T +48.0% | $1.6T +10.4% | $1.4T +15.1% | $1.2T +12.4% | $1.1T | $725.6M | $804.0M | $882.4M |
| Gross Profit | $2.4T -18.7% | $3.0T +6.0% | $2.8T +1.8% | $2.8T +13.0% | $2.5T | $8.9B | $7.6B | $6.2B |
| Gross Margin | 51.1% -14.4pp | 65.5% -0.9pp | 66.4% -2.7pp | 69.1% +0.1pp | 69.0% | 9.8% | 28.9% | 38.3% |
| Research & Development | $716.7B -1.9% | $730.2B +0.0% | $729.9B +15.3% | $633.3B +20.4% | $526.1B | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $1.1T +4.1% | $1.1T +4.8% | $1.1T +5.7% | $997.3B +12.5% | $886.4B | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $1.9T -29.8% | $2.7T +1.5% | $2.6T +14.2% | $2.3T +14.6% | $2.0T | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $764.6B +0.4% | $761.4B +18.1% | $644.5B -3.0% | $664.4B +13.9% | $583.2B | $374.2M | $1.2B | $631.8M |
| EBITDA | $1.4T +17.3% | $1.2T +5.8% | $1.1T -10.9% | $1.3T +8.5% | $1.2T | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | 29.7% +3.3pp | 26.4% -0.4pp | 26.8% -5.1pp | 31.9% -1.3pp | 33.2% | 5.6% | 46.3% | 42.0% |
| Operating Income | $573.0B +67.3% | $342.6B +60.0% | $214.1B -56.4% | $490.5B +6.4% | $460.8B | $12.3B | $14.0B | -$15.7B |
| Operating Margin | 12.0% +4.5pp | 7.5% +2.5pp | 5.0% -7.2pp | 12.2% -0.7pp | 12.9% | 16.6% | 24.1% | 22.0% |
| Interest Income | $223.9B +1040.2% | $19.6B +25045.7% | $78.1M -98.6% | $5.5B +20.0% | $4.6B | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $379.1B +176.1% | $137.3B +12824.1% | $1.1B -99.1% | $117.0B -4.5% | $122.4B | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | -$297.2B -77.4% | -$167.5B -3.9% | -$161.3B -39.7% | -$115.4B +27.1% | -$158.3B | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | $275.9B +57.6% | $175.1B +231.7% | $52.8B -85.9% | $375.1B +24.0% | $302.6B | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | 5.8% +2.0pp | 3.8% +2.6pp | 1.2% -8.1pp | 9.3% +0.8pp | 8.5% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $72.3B +8.0% | $66.9B +173.2% | -$91.4B -257.5% | $58.1B -19.8% | $72.4B | $1.3B | -$1.6B | $745.2M |
| Net Income | $203.3B +88.4% | $107.9B -25.1% | $144.1B -54.6% | $317.0B +37.8% | $230.1B | $4.9B | $4.8B | $4.7B |
| Net Margin | 4.3% +1.9pp | 2.4% -1.0pp | 3.4% -4.5pp | 7.9% +1.4pp | 6.4% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | $64 +87.0% | $34 -25.8% | $46 -54.9% | $102 +38.8% | $74 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | $64 +90.1% | $34 -26.2% | $46 -54.9% | $101 +38.4% | $73 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $3.2B -1.9% | $3.2B +2.6% | $3.1B +0.8% | $3.1B -0.7% | $3.1B | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $3.2B -0.2% | $3.2B +1.6% | $3.2B +0.7% | $3.1B -0.5% | $3.2B | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Becton, Dickinson and Company
NYSE:BDX
$52.98B
Cardinal Health, Inc.
NYSE:CAH
$52.43B
Edwards Lifesciences Corporation
NYSE:EW
$49.01B
Haleon plc
NYSE:HLN
$40.31B
Agilent Technologies, Inc.
NYSE:A
$36.67B
Alcon Inc.
NYSE:ALC
$32.58B
IQVIA Holdings Inc.
NYSE:IQV
$30.29B
ResMed Inc.
NYSE:RMD
$28.25B
Veeva Systems Inc.
NYSE:VEEV
$25.92B
Insmed Incorporated
NASDAQ:INSM
$21.21B
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does TAK generate?
Takeda Pharmaceutical Company Limited (TAK) reported $4.78T of revenue in fiscal 2025.
Is TAK profitable?
Takeda Pharmaceutical Company Limited (TAK) reported $203.33B of net income, with a net margin of 4.3%.
Explore More
Continue the stock analysis
Jump to another research area for this company.